H02

General Information


DRACP ID  DRACP01526

Peptide Name   H02

Sequence  RNRVKXVNLXFATLREH

Sequence Length  17

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetics

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
NCI-H524 Lung small cell carcinoma; Small cell lung cancer Carcinoma EC50≈15 μM MTT assay Not available Patent
NCI-H526 Lung small cell carcinoma; Small cell lung cancer Carcinoma EC50≈10 μM MTT assay Not available Patent

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antitumor



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence

Chiral  L



Physicochemical Information


Formula  C81H133N29O19

Absent amino acids  CDGIMPQSWY

Common amino acids  R

Mass  232269

Pl  12.22

Basic residues  5

Acidic residues  1

Hydrophobic residues  6

Net charge  4

Boman Index  -5492

Hydrophobicity  -65.88

Aliphatic Index  85.88

Half Life 
  /

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  3

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2021/0230226 A1

Patent Title  Anticancer Peptides

Other Iinformation  Patent Application; Family: 8s / 8ex; Family Jurisdictions: CN, EP, CA, JP, AU, WO, US, KR; Legal Status: Pending; Application No: 201816634067; Filed: Jul 24, 2018; Published: Jul 29, 2021; Earliest Priority: Jul 25, 2017

Other Published ID  AU2018305923A1  CA3070874A1  CN111263768A  EP3658576A1  JP2020528458A  KR20200032183A  WO2019020649A1 




DRACP is developed by Dr.Zheng's team.